and Pfizer's Elrexfio (elranatamab). On GSK's third-quarter results call, chief commercial Luke Miels said there is an ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...
after Pfizer acquired Array in 2019. Thomas also held leadership posts with Novartis, Bristol-Myers Squibb, Beigene, GSK and ...
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
ViiV Healthcare Announces Data Demonstrating Dovato (DTG/3TC) Is Highly Effective in Treatment-Naïve People With Advanced HIV ...
GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...
GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.
Medpage Today on MSN3d
Which High-Risk Patients Should Get the RSV Vaccine?The shift to a clear recommendation for vaccination goes beyond the prior guidance "just to encourage adults to talk to their ...
GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback